Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
about
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysisPI3K mutations in breast cancer: prognostic and therapeutic implicationsOvarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypesCharacterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingFar beyond the usual biomarkers in breast cancer: a review.MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysisRelationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.Identification of estrogen receptor proteins in breast cancer cells using matrix-assisted laser desorption/ionization time of flight mass spectrometry (Review).Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapyPIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
P2860
Q26830671-AC64E7B0-5BDB-4EEA-9103-6F4093EBA6EDQ28081992-FB2AA64B-FB83-475F-91FF-54119ED5996FQ28543021-34036806-793A-463B-9CC6-3952A8114A1AQ33716499-51F5F1A7-E6EC-477D-BDD4-EE3A9692E607Q33935217-EB7C5478-8313-4649-BD5E-82464EE10A0CQ34484638-B441FBEE-D049-4EC4-8E2C-5594A6D9B1F1Q34486201-F957BE66-628B-4649-9F93-30A078CA57EEQ34539092-3E3B3974-E26D-40C1-9E4C-384B98119B8BQ35157380-BE892A18-0543-4997-84A8-E4486FF15E91Q35801713-DFFCE7C6-FAF3-4F76-A85E-EF2CD6B3BDE3Q35951988-CBF5BEC7-958A-453F-B54C-CD6E8D5BC607Q36878697-5836894A-3838-47B5-8E65-69333289E056Q37702222-8B1295D1-B774-4E83-BEB9-25019A6E47D1Q38376017-DC3F7287-9CC9-4B31-A9E4-1E0433B0DCBFQ38651789-DB0FB553-B565-4A28-948C-F1082CE25B4EQ38752466-DC2DD1BB-B1D6-478F-8F83-7F02E64F3A68Q41063959-A75656BF-456D-4AA7-8C54-145B47329284Q41472845-45999A4B-64BC-4913-A7C1-33D52A4CCD8EQ42282812-4166C782-12CA-40F0-9B2C-4998D45F4F56Q47584016-D38804F1-A2A1-42B3-AE82-5674B3AD5C67Q51295443-AB52E2B6-936E-4447-8BF9-44431395D226
P2860
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@en
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@nl
type
label
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@en
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@nl
prefLabel
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@en
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@nl
P2093
P2860
P1476
Hotspot mutations in PIK3CA as ...... ibitors but not for tamoxifen.
@en
P2093
Diana E Ramirez-Ardila
Els M J J Berns
Fred C Sweep
Irene Lurkin
Jean C Helmijr
John A Foekens
Kirsten Ruigrok-Ritstier
Maurice P H M Jansen
Maxime P Look
P2860
P2888
P356
10.1007/S10549-013-2529-7
P407
P577
2013-04-17T00:00:00Z